Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 7.88M | 5.69M | 21.94M | 2.15M | 2.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.88M | 5.69M | 21.94M | 2.15M | 2.95M |
| Cost of Revenue | 48.51M | 6.40M | 15.93M | 4.15M | 7.11M |
| Gross Profit | -40.63M | -711.00K | 6.01M | -2.01M | -4.16M |
| SG&A Expenses | 47.07M | 4.65M | 4.05M | 5.54M | 4.48M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 95.57M | 11.05M | 19.98M | 9.69M | 11.59M |
| Operating Income | -87.70M | -5.36M | 1.96M | -7.54M | -8.64M |
| Income Before Tax | -153.07M | -5.18M | 2.09M | -7.45M | -8.48M |
| Income Tax Expenses | -- | -- | 500.00K | -- | -- |
| Earnings from Continuing Operations | -153.07M | -5.18M | 1.59M | -7.45M | -8.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -153.07M | -5.18M | 1.59M | -7.45M | -8.48M |
| EBIT | -87.70M | -5.36M | 1.96M | -7.54M | -8.64M |
| EBITDA | -87.66M | -4.80M | 2.64M | -7.46M | -8.54M |
| EPS Basic | -24.14 | -1.08 | 0.44 | -2.22 | -2.67 |
| Normalized Basic EPS | -15.09 | -0.67 | 0.36 | -1.38 | -1.67 |
| EPS Diluted | -24.14 | -1.08 | 0.43 | -2.22 | -2.67 |
| Normalized Diluted EPS | -15.09 | -0.67 | 0.35 | -1.38 | -1.67 |
| Average Basic Shares Outstanding | 6.34M | 4.81M | 3.60M | 3.36M | 3.18M |
| Average Diluted Shares Outstanding | 6.34M | 4.81M | 3.68M | 3.36M | 3.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |